Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
HUTCHMED (China) Limited (GB:HCM)
LSE:HCM
RESEARCH TOOLSreports
HUTCHMED (China) Limited (HCM) Share Forecast & Price Target
2 Followers
See the Price Targets and Ratings of:
HCM Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HCM Stock 12 Month Forecast
Average Price Target
353.99p
▲(20.82% Upside)
| Highest Price Target353.99p | Average Price Target353.99p | Lowest Price Target353.99p |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
UBS
353.99p
Buy
353.99p
(20.81% Upside)
Initiated
04/23/24
UBS Starts Hutchmed China Ltd (13:HK) at BuyUBS analyst Chen Chen initiates coverage on Hutchmed China Ltd (13:HK) with a Buy rating and a price target of HK$35.70.
CMB International Securities
340.2p
Buy
340.20p
(16.11% Upside)
Reiterated
03/01/24
We anticipate the US NDA submission for accelerated approval by the end of 2024, and savolitinib potentially to be positioned as HCM's second product to reach the global market. Compared with other competing therapies, savolitinib + osimertinib offers potentially better efficacy for specific MET+ patients, and its oral administration route is more convenient over other competing therapies. In China, savolitinib has the potential to expand its label into 1L MET Exon 14 NSCLC with the filing expected in 1Q24E based on positive results from confirmatory Ph3b study.
Goldman Sachs
1,161.35p→1,316.19p
Hold
1,316.19p
(349.21% Upside)
Reiterated
11/10/23
Hutchison China MediTech Ltd. (HCM) PT Raised to $17 at Goldman SachsGoldman Sachs analyst Paul Choi raised the price target on Hutchison China MediTech Ltd. (NASDAQ: HCM) to $17.00 (from $15.00) while maintaining a Neutral rating.
Citi
317.3p→396.62p
Buy
396.62p
(35.37% Upside)
Reiterated
11/10/23
Hutchmed China Ltd (13:HK) PT Raised to HK$40 at CitiCiti analyst John Yung raised the price target on Hutchmed China Ltd (13:HK) to HK$40.00 (from HK$32.00) while maintaining a Buy rating.
CLSA
380p→390p
Buy
390.00p
(33.11% Upside)
Reiterated
08/03/23
HUTCHMED China Ltd (HCM:LN) PT Raised to GBP3.90 at CLSACLSA analyst Matthew Yan raised the price target on HUTCHMED China Ltd (HCM:LN) to GBP3.90 (from GBP3.80) while maintaining a Buy (1) rating.
Best Analysts Covering HUTCHMED (China) Limited
Which Analyst Should I Follow If I Want to Buy GB:HCM and Sell After:
1 Month
xxx
Success Rate
2/3 ratings generated profit
Average Return
+4.57%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.57% per trade.
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+11.97%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.97% per trade.
1 Year
Success Rate
2/3 ratings generated profit
Average Return
+15.30%
reiterated a buy rating 5 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +15.30% per trade.
2 Years
xxx
Success Rate
2/3 ratings generated profit
Average Return
+15.30%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +15.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HCM Analyst Recommendation Trends
Rating
Jun 23
Aug 23
Nov 23
Mar 24
Apr 24
Strong Buy
0
0
0
0
0
Buy
2
4
6
6
4
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
5
7
7
5
Each month's total comprises the sum of three months' worth of ratings.
HCM Financial Forecast
HCM Stock Forecast FAQ
What is GB:HCM’s average 12-month price target, according to analysts?
Based on analyst ratings, HUTCHMED (China) Limited’s 12-month average price target is 353.99p.
What is GB:HCM’s upside potential, based on the analysts’ average price target?
HUTCHMED (China) Limited has 20.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HUTCHMED (China) Limited a Buy, Sell or Hold?
HUTCHMED (China) Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is HUTCHMED (China) Limited’s share price target?
The average share price target for HUTCHMED (China) Limited is 353.99p. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 353.99p ,and the lowest forecast is 353.99p. The average share price target represents 20.82% Increase from the current price of 293p.
The highest analyst share price target is 353.99p ,and the lowest forecast is 353.99p. The average share price target represents 20.82% Increase from the current price of 293p.
What do analysts say about HUTCHMED (China) Limited?
HUTCHMED (China) Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of HUTCHMED (China) Limited?
To buy shares of GB:HCM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.